ACKNOWLEDGMENTS
AIDS, Hutchinson Cancer, HIV vaccine patent, Johnson and Johnson stock
INFECTIOUS DISEASES, ALLERGY, AIDS, FRANK, INFECTIOUS DISEASE
The authors would like to acknowledge collaborators on the APPROACH study: International AIDS Vaccine Initiative (IAVI); HIV Vaccine Trial Network (HVTN); HVTN Laboratory Center and colleagues at Statistical Center for HIV/AIDS Research and Prevention and Fred Hutchinson Cancer Center, especially Daryl Morris; National Institute of Allergy and Infectious Disease (NIAID); the Ragon Institute; the Military HIV Research Program (MHRP); the Bill & Melinda Gates Foundation; Division of AIDS (DAIDS); National Institute of Allergy and Infectious Diseases NIAID; Janssen team members: Frank Tomaka, Ludo Lavreys, Caroline Borremans, Jenny Hendriks, Mariska van Rosmalen.The APPROACH study was Funded by Janssen Vaccines & Prevention B.V., the National Institute of Allergy and Infectious Diseases, and others; APPROACH ClinicalTrials.gov number, NCT02315703 under grants NIH OD024917, AI068618, AI078526, AI096040, AI124377, AI126603, AI128751, TR001102; Ragon Institute of MGH, MIT, and Harvard; a cooperative agreement (W81XWH-07-2-0067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense (DOD); This work was funded by IAVI with the generous support of USAID and other donors; a full list of IAVI donors is available at D.H.B. reports grants from Janssen Vaccines and Prevention outside the submitted work, as well as an HIV vaccine patent licensed to Janssen Vaccines and Prevention. S.C.D. reports grants from the NIH and Gates Foundation during the conduct of the study and a contract from Janssen Vaccines and Prevention outside the submitted work. M.J.M. reports grants from the National Institute of Allergy and Infectious Diseases (NIAID; funding for Seattle CTU Grant and funding for HVTN Lab) during the study. J.D., D.S., J.T., K.C., W.W., and M.G.P. are employees of Janssen and may hold Johnson and Johnson stock.